Evidence map›Paper›PMID 40118946›Full record

Trial reportScientific reports2025

SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial).

Sofía Sábato, Susana Benet, Angela J Rogers, Thomas A Murray, Melissa Skeans, Beatriz Mothe, Roger Paredes, Ahmad Mourad, Francis Kiweewa, Dena Kamel and 31 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Sofía Sábato *Fundació Lluita Contra Les Infeccions, Badalona, Spain.
Susana Benet *Fundació Lluita Contra Les Infeccions, Badalona, Spain.
Angela J RogersDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.
Thomas A MurrayDivision of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, MN, USA.
Melissa SkeansDivision of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, MN, USA.
Beatriz MotheFundació Lluita Contra Les Infeccions, Badalona, Spain.
Roger ParedesFundació Lluita Contra Les Infeccions, Badalona, Spain.
Ahmad MouradDivision of Infectious Diseases, Department of Medicine, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Francis KiweewaStrengthening Institutional Capacity for Research Administration (SICRA), Lira, Uganda.
Dena KamelUT Southwestern Medical Center, Dallas, TX, USA.
Mamta K JainUT Southwestern Medical Center, Dallas, TX, USA.
Joseph LutaakomeMRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda.
Mary Grace NalubegaStrengthening Institutional Capacity for Research Administration (SICRA), Lira, Uganda.
Nicholus SebuddeStrengthening Institutional Capacity for Research Administration (SICRA), Lira, Uganda.
Eleftherios MylonakisDepartment of Medicine, Houston Methodist Hospital, Houston, TX, USA.
Dominique L BraunDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Timothy HatlenThe Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
Ivan KimuliMakerere University Lung Institute, Makerere University, Kampala, Uganda.
Cissy KitkoJoint Clinical Research Centre, Lubowa, Uganda.
Henry MugerwaJoint Clinical Research Centre, Lubowa, Uganda.
Jonathan KitonsaMRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda.
Kami KimTampa General Hospital, University of South Florida, Tampa, FL, USA.
Phyllis C TienDepartment of Medicine, Department of Veterans Affairs Medical Center, University of California, San Francisco, San Francisco, CA, USA.
Jeroen HighbargerNIAID, NIH, FNL (Frederick National Laboratory), Frederick, ML, USA.
Ashley L McCormackLaboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Adriana SanchezInfectious Diseases Section, VA Medical Center, Washington, DC, USA.
Daniel D MurrayDepartment of Infectious Diseases, CHIP Center of Excellence for Health, Immunity, and Infections, Rigshospitalet, Copenhagen, Denmark.
Abdel G BabikerMRC Clinical Trials Unit at UCL, University College London, London, UK.
Victoria J DaveyOffice of Research and Development, US Department of Veterans Affairs, Washington, DC, USA.
D Clark FilesDivision of Pulmonary, Critical Care, Allergy and Immunology, Department of Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
Annetine C GelijnsDepartment of Population Health Science and Policy, Icahn School of Medicine, New York, NY, USA.
Elizabeth S HiggsDivision of Clinical Research, NIAID, NIH, Bethesda, USA.
Virginia L KanVA Medical Center, George Washington University, Washington, DC, USA.
Gail V MatthewsKirby Institute, University of New South Wales, Sydney, Australia.
Sarah L PettMRC Clinical Trials Unit at UCL, University College London, London, UK.
H Clifford LaneNational Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, USA.
Cavan ReillyDivision of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, MN, USA.
Anna L GoodmanMRC Clinical Trials Unit at UCL, University College London, London, UK.
Jens D Lundgren *Department of Infectious Diseases, CHIP Center of Excellence for Health, Immunity, and Infections, Rigshospitalet, Copenhagen, Denmark.
José Moltó *Fundació Lluita Contra Les Infeccions, Badalona, Spain. jmolto@lluita.org.
ACTIV-3/VATICO study group and the STRIVE Network

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Danmarks Grundforskningsfond DNRF 126Medical Research Council MC_UU_00004/03 and MC_UU_00004/04National Health and Medical Research Council Investigator GrantNCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

The impact on immunogenicity and efficacy of SARS-CoV-2 vaccination in people with prior COVID-19 could differ depending on timing of vaccination and number of doses. The VATICO study randomized 66 hospitalized recovered COVID-19 individuals to receive either immediate or deferred vaccination, with one or two doses of mRNA SARS-CoV-2 vaccines. We measured binding and neutralizing antibodies against SARS-CoV-2 at enrollment and longitudinally. Median (IQR) time from SARS-CoV-2 infection to first vaccination was 68 (53-75) days in the immediate group, and 151 (137-173) days in the deferred group. At week 48, timing or number of vaccine doses did not influence the change in antibody levels relative to baseline. Adherence to the assigned vaccine regimen was lower in the deferred group, particularly in participants receiving two doses. Although the study ultimately lacked adequate power to draw firm conclusions, these results suggest possible benefits of prompt vaccination after recovery from COVID-19.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2VaccinationAdultAgedAntibodies, NeutralizingAntibodies, ViralFemaleHospitalizationHumansMaleMiddle AgedAntibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccines

Identifiers

PMID40118946
PMCPMC11932324

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.